Compare · HKPD vs NUS
HKPD vs NUS
Side-by-side comparison of Cellyan Biotechnology Co. Ltd (HKPD) and Nu Skin Enterprises Inc. (NUS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HKPD and NUS operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- NUS is the larger of the two at $370.8M, about 24.5x HKPD ($15.1M).
- Over the past year, HKPD is down 28.6% and NUS is up 28.9% - NUS leads by 57.5 points.
- Both names hit the wire about 1 times in the past 4 weeks.
- NUS has more recent analyst coverage (4 ratings vs 0 for HKPD).
- Company
- Cellyan Biotechnology Co. Ltd
- Nu Skin Enterprises Inc.
- Price
- $0.65-12.02%
- $7.53+0.67%
- Market cap
- $15.1M
- $370.8M
- 1M return
- +0.03%
- +3.29%
- 1Y return
- -28.57%
- +28.94%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- 1996
- News (4w)
- 1
- 1
- Recent ratings
- 0
- 4
Nu Skin Enterprises Inc.
Nu Skin Enterprises, Inc. develops and distributes personal care and wellness products worldwide. It provides skin care systems, including ageLOC Me customized skin care and ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products comprising botanical ingredients derived from renewable sources, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, and LifePak nutritional supplements, as well as other anti-aging nutritional solutions and weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
Latest HKPD
- SEC Form EFFECT filed by Cellyan Biotechnology Co. Ltd
- SEC Form F-1 filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
- SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
- SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
- Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders
- SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
Latest NUS
- Nu Skin Enterprises to Announce First Quarter 2026 Financial Results
- SEC Form DEFA14A filed by Nu Skin Enterprises Inc.
- SEC Form DEF 14A filed by Nu Skin Enterprises Inc.
- Nu Skin Launches Prysm iO™: A Revolutionary AI-Powered Platform for Personalized Nutritional Wellness
- SEC Form 3 filed by new insider Lantz Chelsea K
- Nu Skin Enterprises Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13G/A filed by Nu Skin Enterprises Inc.
- Nu Skin Enterprises Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer
- Director Woodbury Edwina D was granted 14 shares, increasing direct ownership by 0.03% to 42,993 units (SEC Form 4)